About Organoid Research

Organoid Research

Organoid Research is an international, peer-reviewed, open-access journal dedicated entirely to organoid science. It is owned by AccScience Publishing, with academic support from the Institute of Translational Medicine of Shanghai University, and it was launched in 2025, publishing four issues in its first volume, beginning with Issue 1 on 25 March 2025, and continuing with Volume 2 in 2026. Its founding Editors-in-Chief are Changsheng Liu and Jiacan Su of Shanghai University. The journal carries online ISSN 3082-8503 and publishes under DOI prefix 10.36922, and every article appears as gold open access under a Creative Commons Attribution 4.0 International licence.

What an organoid journal is for

Organoids are three-dimensional structures grown from stem cells or tissue-derived cells that reproduce key features of real organs. Research using them has expanded quickly because such systems sit between conventional cell culture and animal or human studies: they can model development and disease, and they can be used to test drugs on material that behaves more like human tissue. Organoid Research was founded to give that fast-moving field a dedicated home. AccScience describes it as a journal for studies that provide significant conceptual, experimental and translational advances in the development and application of organoid technologies, and states its ambition plainly: with a focus on timely peer review and publication, it aims to be the leading platform for scientists, engineers and clinicians working at the forefront of organoid technology.

Ownership and academic support in Shanghai

The journal is owned by AccScience Publishing, and its own journal policies name the source of its academic support: the Institute of Translational Medicine of Shanghai University. That institute is part of the same Shanghai University research environment in which the journal's founding editors work, including the Organoid Research Center and the National Center for Translational Medicine (Shanghai) SHU Branch at Shanghai University, whose address is given in published research from the group as No. 99 Shangda Road, Baoshan District, Shanghai. This anchoring matters for a new specialist journal: submissions, editorial judgement and scholarly networks are tied to an institution actively researching organoids, while the publisher provides the journal platform, production and open-access distribution through its website at accscience.com.

Founding editors Changsheng Liu and Jiacan Su

The founding Editors-in-Chief are Changsheng Liu and Jiacan Su of Shanghai University. Jiacan Su's role is visible in the journal's early content and in related scholarship: he is a co-author of the review “Organoid research breakthroughs in 2024”, published in the journal in 2025, which surveyed how refinement of culture protocols for generating more physiologically relevant organoids from a wide range of human tissues — facilitated by improved differentiation protocols for induced pluripotent stem cells and adult stem cells — had advanced disease modelling, drug discovery and regenerative medicine. That review also illustrates the journal's editorial practice: where an editor is an author, the published article states that the Editor-in-Chief was not involved in the editorial and peer-review process for that paper. Naming its founding editors and showing that separation in print are basic but important credibility signals for a journal in its first volumes.

Scope: from stem cells to clinical translation

The journal welcomes submissions across the breadth of organoid science, including stem cell biology, tissue engineering, regenerative medicine, disease modelling and drug discovery. It encourages papers on bioengineered organoids, organoid-based systems biology and the integration of organoids with clinical research. Special emphasis is placed on contributions that advance novel approaches to organoid development, including cutting-edge bioengineering techniques, materiobiology and integrative technologies such as artificial intelligence, high-throughput screening and precision medicine. It also values research on the ethical considerations and challenges related to the clinical translation of organoid systems — an acknowledgement that growing organ-like structures from human cells raises questions that purely technical papers cannot settle.

Article types and special collections

Organoid Research publishes high-quality research articles, reviews and perspectives. Reviews have played a prominent role in its first volumes, mapping a field that changes technique by technique: the 2024 breakthroughs review, for example, organised recent progress around culture protocols, stem-cell differentiation and applications in disease modelling, drug discovery and regenerative medicine, with keywords spanning organoids, induced pluripotent stem cells, disease modelling, drug discovery and biomaterials. The journal also runs themed columns and special issues chosen by the Editor-in-Chief's and editorial board's teams around future academic trends and research hotspots. One announced collection, “Organoids and Aging Research: From Model Construction to Anti-Aging Interventions”, invites original research, reviews and perspectives on using organoids — which can closely mimic the structure and function of human organs — to elucidate mechanisms of age-related disease, screen drugs and develop personalised therapeutic strategies.

Publication history: Volumes 1 and 2

The journal's publication record began quickly. Volume 1 appeared in 2025 with four issues, the first dated 25 March 2025, and Volume 2 followed in 2026. Articles are identified by DOIs under the prefix 10.36922, AccScience's prefix, and the journal's online ISSN is 3082-8503. A quarterly rhythm in a launch year is a demanding schedule for a niche title, and sustaining it into a second volume indicates a working pipeline of submissions from the organoid community. Early content also shows the journal publishing forward-looking review material that connects organoids with microfluidics, gene editing and artificial intelligence — combinations its aims and scope explicitly encourage under integrative technologies and precision medicine.

Open access and licensing

Organoid Research is a gold open-access journal: all articles are made freely and permanently accessible online immediately from the date of publication, and articles are published under CC BY 4.0, the Creative Commons Attribution licence that allows sharing and reuse with attribution. For a methods-driven field, immediate free access has practical value — a laboratory deciding how to build or culture an organoid system can read the relevant protocol or review without a subscription barrier, and clinicians and engineers outside the originating discipline can follow developments that may affect drug testing or regenerative therapies. The publisher states that the journal focuses on timely peer review and publication, pairing that speed claim with peer review as the condition for the research articles, reviews and perspectives it accepts.

Interdisciplinary reach

The journal explicitly addresses scientists, engineers and clinicians together, and seeks to foster innovation and interdisciplinary collaboration. That triad reflects how organoid work is actually done: stem-cell biologists generate the systems, engineers build the scaffolds, microfluidic devices and screening platforms around them, and clinicians define the disease questions and the route to translation. Organoid Research's scope follows that workflow, from stem cell biology and tissue engineering through disease modelling and drug discovery to clinical research and precision medicine, with bioengineering techniques, materiobiology, artificial intelligence and high-throughput screening named as integrative approaches. Even its treatment of ethics — welcoming work on the challenges of clinical translation — treats the social and medical dimensions of the technology as part of the science rather than an afterthought.

Place in the organoid literature

Organoid Research is not the only journal with organoids in its sights, which makes its specific identity important: it is a dedicated, China-supported, fully open-access title owned by AccScience, academically supported by Shanghai University's Institute of Translational Medicine, and led from Shanghai University by Changsheng Liu and Jiacan Su. Its first two volumes, quarterly launch schedule, special collections on topics such as ageing, and stated aim to be the leading platform for the field give it a clear profile for authors deciding where a manuscript on organoid development, bioengineered systems, disease models or drug discovery belongs. Readers can browse its issues and its aims, scope and journal policies on the AccScience website, where the journal's ownership, licensing and peer-review arrangements are published in full.